The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Chrono-log sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Chrono-log is a technology company that designs, develops and manufactures innovative platelet technologies for platelet function testing in clinical and research laboratories. It offers a complete line of aggregation and lumi-aggregation systems, CHRONO-PAR and CHRONO-LUME reagents and supplies, providing a single source for all the platelet testing needs. These tools are used in the diagnosis of platelet function defects such as Von Willebrand disease, Glanzmann’s thrombasthenia, storage pool disease and secretion defects; monitoring of anti-platelet drugs and assisting researchers in developing therapies. It serves hospitals, medical centres, universities, clinical and research laboratories, and pharmaceutical companies. Chrono-log is headquartered in Havertown, Pennsylvania, the US.
The key metrics of Chrono-log related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Chrono-log is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Chrono-log.
For a detailed understanding of the performance of Chrono-log, buy the report here.